Related Experiment Video
Updated: Sep 11, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
Ganoderic acid A alleviate psoriasis by inhibiting GSDMD-mediated pyroptosis
Chenggen Xiao1, Junchen Chen2, Xingchen Zhou2
1Department of Emergency, Xiangya Hospital, Central South University, Changsha, China; Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China.
Tissue & Cell
|August 16, 2025
Summary
Ganoderic acid A effectively treats psoriasis by reducing skin inflammation and inhibiting pyroptosis. This natural compound shows promise as a therapeutic agent and dietary recommendation for psoriasis patients.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Psoriasis is a chronic inflammatory skin disease.
- Inflammatory cell infiltration characterizes psoriatic lesions.
- Understanding new therapeutic targets is crucial.
Purpose of the Study:
- To investigate the anti-inflammatory effects of Ganoderic acid A on psoriasis.
- To elucidate the molecular mechanisms of Ganoderic acid A in psoriasis treatment.
Main Methods:
- A mouse model of psoriasis was induced using imiquimod (IMQ).
- Psoriasis Area and Severity Index (PASI) scores were used to assess inflammation.
- Histopathology (hematoxylin-eosin staining), RNA sequencing, and immunofluorescence assays were performed.
Main Results:
- Ganoderic acid A, administered intraperitoneally and topically, reduced psoriasis severity.
- Treatment decreased skin thickness, erythema, and scaling.
- Ganoderic acid A inhibited pyroptosis via the GSDMD pathway, reducing inflammatory cytokine secretion.
Conclusions:
- Ganoderic acid A demonstrates significant therapeutic potential for psoriasis.
- The compound effectively modulates key inflammatory pathways.
- Ganoderic acid A may be a valuable addition to psoriasis management strategies.
Related Concept Videos
01:24T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
01:12GPCR Desensitization
6.5K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
596
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
596
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
203
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
203